Journal of biomedical science

Using Artificial Intelligence to Develop Personalized Cancer Vaccines Targeting Unique Tumor Markers

Updated

Abstract

Personalized neoantigen cancer vaccines show early promise in immunotherapy, with feasibility and safety demonstrated across multiple solid tumors.

  • Early clinical studies indicate that these vaccines can effectively target patient-specific tumor antigens derived from mutations.
  • Combining personalized neoantigen vaccines with immune checkpoint blockade has led to encouraging outcomes.
  • Key translational barriers include issues with neoantigen selection, antigen processing modeling, and T-cell receptor recognition prediction.
  • Artificial intelligence and computational methods may enhance the vaccine development pipeline by improving candidate prioritization and decision-making.
  • Four major stages for AI integration include neoantigen discovery, HLA presentation prediction, immunogenicity modeling, and formulation optimization.
  • Challenges for future implementation encompass dataset diversity, model interpretability, and regulatory frameworks for individualized therapies.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free